Opus Genetics FDA alignment further de-risks path to market, says Chardan
After Opus Genetics announced that it has reached alignment with the FDA on the design of its registrational Phase 3 clinical trial evaluating OPGx-LCA5 for LCA5-associated IRD, an early-onset severe inherited retinal dystrophy, Chardan calls today's announcement a positive for OPGx-LCA5 as well as one that has an "encouraging read through" to the potential streamlined regulatory path for OPGx-BEST1 ahead of upcoming cohort 1 data in September. The firm has a Buy rating and $13 price target on Opus shares.
After Opus Genetics announced that it has reached alignment with the FDA on the design of its registrational Phase 3 clinical trial evaluating OPGx-LCA5 for LCA5-associated IRD, an early-onset severe inherited retinal dystrophy, Chardan calls today's announcement a positive for OPGx-LCA5 as well as one that has an "encouraging read through" to the potential streamlined regulatory path for OPGx-BEST1 ahead of upcoming cohort 1 data in September.
The firm has a Buy rating and $13 price target on Opus shares.